A federal appeals court upheld two patents protecting Amgen’s blockbuster drug, Enbrel, against biosimilar competition, Biopharma Dive reported. Amgen has been in a yearslong legal battle with the ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a biosimilar product in the United States to compete with Amgen's blockbuster Enbrel ...

Generic drugmaker Sandoz (OTCQX:SDZXF) announced on Monday the filing of an antitrust lawsuit alleging that Amgen (NASDAQ:AMGN) used certain patent-related tactics to extend its U.S. market dominance ...

Negotiations to set prices Medicare will pay for the original branded version of etanercept, Enbrel, should bring the government some genuine savings, and may indirectly make it more affordable for ...